Skip to Content

Eli Lilly and Co

LLY: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$189.00QczyCrzhhzngw

Eli Lilly: Positive Tirzepatide Data in Obstructive Sleep Apnea Reinforces Drug's Massive Potential

We are holding our fair value estimate for Eli Lilly steady after the company reported positive tirzepatide (Mounjaro/Zepbound) data in treating obstructive sleep apnea and obesity. We had largely expected the positive results, which support our robust peak annual sales forecast for the drug at over $60 billion annually across all indications. The solid data does help reinforce the company’s wide moat.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of LLY so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center